Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Posted on December 11, 2012 at 07:26 AM EST
Isis Pharmaceuticals (NASDAQ: ISIS ) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with